Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K45/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/167827COMPOSITION FOR CONTROLLING AND/OR PREVENTING OXIDATIVE STRESS COMPRISING AT LEAST S-ADENOSYL METHIONINE AND ASTRAGALUS SP. POLYSACCHARIDES
WO 11.08.2022
Int.Class A61K 31/7076
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
7064containing condensed or non-condensed pyrimidines
7076containing purines, e.g. adenosine, adenylic acid
Appl.No PCT/IB2021/000049 Applicant IDEC THERAPEUTIC Inventor FREY, Michel
Compositions intended for controlling and/or preventing oxidative stress, particularly in a human being, in optimizing GSH/GSSG blood serum ratio. Such a composition comprising at least S-adenosyl methionine and Astragalus sp. polysaccharides, can be used as a food supplement or as a composition for topical application such as a cosmetic and/or dermatological and/or pharmaceutical cream or gel.
2.WO/2022/167652SUPPLEMENT FOR ARTHRITIS AND PSORIASIS
WO 11.08.2022
Int.Class A61K 9/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
Appl.No PCT/EP2022/052873 Applicant CS MEDICA A/S Inventor HENRIKSEN, Lone
The present invention relates to an oral composition for use in the treatment and/or alleviation of symptoms such as pain and/or discomfort in a subject, such as pain or discomfort related to arthritis, or psoriasis. Such a treatment may further comprise application of a cannabinoid-comprising topical composition, such a CBD-comprising composition, such as a CBD-comprising hydroalcoholic gels. Different compositions comprising 3‐O‐Acetyl-11‐Keto Beta Boswellic Acid, Curcuminoid, Vitamin C, and Vitamin D are disclosed.
3.WO/2022/167697HETEROAROMATIC SPERMIDINE ANALOGUES AND THEIR ANTICANCER ACTIVITY
WO 11.08.2022
Int.Class A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Appl.No PCT/EP2022/053044 Applicant FLORATEK PHARMA SA Inventor STOICESCU, Dan Florin
The present invention relates to chromen-4-one derivatives, and to associated multi-salts, solvates, prodrugs and pharmaceutical compositions. The present invention also relates to the use of such compounds and compositions in the treatment and prevention of cancer.
4.WO/2022/166796PYRIMIDINE OR PYRIDINE AND HETEROCYCLIC ADENOSINE RECEPTOR INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF
WO 11.08.2022
Int.Class C07D 487/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Appl.No PCT/CN2022/074495 Applicant SHANGHAI QILU PHARMACEUTICAL RESEARCH AND DEVELOPMENT CENTRE LTD. Inventor PAN, Jianfeng
Disclosed are a novel pyrimidine/pyridine and heterocyclic adenosine receptor inhibitor, a preparation method therefor and use thereof. The novel pyrimidine/pyridine and heterocyclic adenosine receptor inhibitor is a compound as represented by formula II, a pharmaceutically acceptable salt thereof, a solvate thereof, or a solvate of the pharmaceutically acceptable salt thereof. Drug activity data shows that the compounds have a better inhibitory effect on A2a or/and A2b, and some compounds exhibit better selectivity, and can be used for treating diseases related to A2a or/and A2b receptors.
5.WO/2022/169961SIGMA RECEPTOR LIGANDS FOR TREATING SARS-COV-2 INFECTION
WO 11.08.2022
Int.Class A61K 41/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
41Medicinal preparations obtained by treating materials with wave energy or particle radiation
Appl.No PCT/US2022/015096 Applicant UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED Inventor MCCURDY, Christopher, R.
The invention relates to compounds, compositions, and methods of treating viral infection, especially SARS-CoV-2 infection.
6.WO/2022/170081ANTIARRHYTHMIC FORMULATION
WO 11.08.2022
Int.Class A61K 31/165
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
16Amides, e.g. hydroxamic acids
165having aromatic rings, e.g. colchicine, atenolol, progabide
Appl.No PCT/US2022/015293 Applicant INCARDA THERAPEUTICS, INC. Inventor SCHULER, Carlos
Pharmaceutical compositions comprising an antiarrhythmic agent for treatment of a heart condition via inhalation are disclosed. Methods of treating a heart condition disclosed herein include administering by inhalation an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof. Dry powder drug product and kits are also disclosed.
7.WO/2022/169705CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
WO 11.08.2022
Int.Class A61K 31/585
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopentahydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
58containing heterocyclic rings, e.g. aldosterone, danazol, stanozolol, pancuronium, digitogenin
585containing lactone rings, e.g. oxandrolone, bufalin
Appl.No PCT/US2022/014524 Applicant NEUPHARMA, INC Inventor QIAN, Xiangping
Chemical entities that are novel compounds, their polymorphs, pharmaceutical compositions, and methods of treatment of cancer are described.
8.WO/2022/169973DIETARY SUPPLEMENT FOR IMPROVING BRAIN PERFORMANCE
WO 11.08.2022
Int.Class A61P 25/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
Appl.No PCT/US2022/015114 Applicant NATRILLO, Richard Inventor NATRILLO, Richard
Disclosed herein is a dietary supplement containing alpha-glyceryl phosphoryl choline, phosphatidylserine, and an alkalizing agent, and its use in methods of maintaining or improving brain functions, such as mental focus, clarity, long-term memory, short-term memory, analytical reasoning, higher learning, mental processing, mental clarity, creativity, procrastination, willpower, reasoning, mood, retrieval/recall, learning gradient, and reaction time. The supplement can also be used in methods of treating or preventing cognitive dysfunction and dementia.
9.WO/2022/166909USE OF PPAR-DELTA INHIBITOR IN COMBINATION WITH IMMUNOTHERAPEUTIC DRUG FOR PREPARING ANTI-TUMOR DRUG
WO 11.08.2022
Int.Class A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Appl.No PCT/CN2022/075135 Applicant THE FIRST HOSPITAL OF JILIN UNIVERSITY Inventor LIU, Wentao
It relates to a pharmaceutical use of a PPARδ inhibitor in combination with an immunotherapeutic drug for preparing an anti-tumor drug, wherein the immunotherapeutic drug is an immune agonist or an immune checkpoint inhibitor, the tumor is preferably melanoma, mammary cancer, ovarian cancer, pancreatic cancer, lung cancer, liver cancer, esophageal cancer, colorectal cancer, colonic cancer, lymphoma, brain tumor, sarcoma, cervical cancer, prostate cancer, bladder cancer, osteosarcoma, head and neck cancers, renal cell carcinoma, or stomach cancer. The medicine exhibits significant anti-cancer effect, strong targeting ability which has little side effect.
10.WO/2022/168004CARDIOVASCULAR DISEASE MEDICATION ADMINISTRATION METHODS
WO 11.08.2022
Int.Class A61K 31/41
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
Appl.No PCT/IB2022/051006 Applicant AORTO MEDICAL LLC Inventor EL AZOUZI, Youssef
Medication administration methods are provided for treating cardiovascular disease. A method may include administering a baseline dosage of the medication to a patient. A flow diverting apparatus may be implanted into a vessel of the patient such that blood pressure to the patient's kidneys is increased. The flow diverting apparatus is structured to partially occlude blood flow through the vessel when implanted thereby increasing upstream blood pressure. Subsequent to implanting the flow diverting apparatus, the medication dosage may be increased above, or decreased below, the baseline dosage. The dosage may be increased if the medication is a beta-blocker, an angiotensin-receptor blocker, an angiotensin receptor enzyme inhibitor, a chymase inhibitor, a combination of an angiotensin receptor enzyme inhibitor and an angiotensin-receptor blocker, or a combination of an angiotensin receptor blocker and a neprilysin-inhibitor. The dosage may be decreased if the medication is a diuretic.